Table 2 Clinical characteristics and treatment of reported patients with secondary amyloidosis related to juvenile idiopathic arthritis
Reference | Age (y)/Sex | Duration of JIA before diagnosis of amyloidosis (y) | Systemic features of JIAa | ESR or CRP, Initial to last FU (mm/h or mg/dL) | Organ involvement of amyloidosis | eGFR, initial to last FU (mL/1.73 m2/min) | Proteinuria, Initial to last FU (mg/day) | Treatment before diagnosis of amyloidosis | Additive treatment after diagnosis of amyloidosis | Duration of FU after diagnosis of amyloidosis | Efficacy of amyloidosis treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
Duarte et al. 2005 [18] | 9/F | 5.5 | Yes | ESR 125 to 27 | Renal | NA | UPCR (mg/mmol) 1057 to 47 | MTX, CSA, GCs, and ETA | CRB | 14 months | Yes |
Okuda et al. 2006 [30] | 26/F | 12 | No | CRP 15 to 0.03 | GI, Renal | 66 to 124 | 700 to normal | ATM, BCL, D-PEN, SFZ, MTX, and GCs | TCZ | 42 months | Yes |
Nowak et al. 2009 [31] | 31/F | 10 | No | ESR 40 to 26 | Renal | 38.6 to 140 | 5600 to <1100 | CRB, GCs, and various DMARDs | ADA | 20 weeks | Yes |
Cantarini et al. 2009 [8] | 9/F | 2 | Yes | CRP 14.7 to NA | Renal | NA | 18,130 to NA | MTX, CSA, and GCs | COL, ↑ dose of MTX | NA (lost to FU) | NA (lost to FU) |
Hakala et al. 2013 [32] | 29/F | 23 | NA | CRP 64 to normal | Renal | 27 to 51 | 1300 to normal | CYC, GCs, and various DMARDs | ADA, ETA, INF, ANA, ABA, TCZ | 24 months | Yes |
Saha et al. 2013 [19] | 12/F | 3 | Yes | NA | Renal | 128 to 128 | UPCR (mg/g) 12.5 to 1.5 | MTX, HCQ, and GCs | LFN | 18 months | Yes |